Compare Under Armour Inc Class A (UAA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs Vertex Pharmaceuticals Incorporated — how do they compare? Under Armour Inc Class A trades at $5.36 (market cap $2.57B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 51.7× Under Armour Inc Class A's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| UAA | VRTX | |
|---|---|---|
Market Cap | $2.57B | $132.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.14 | $529.65 |
52-Week Low | $4.17 | $376.62 |
Enterprise Value | $3.55B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UAA) trades at $6.11, down 4.38% today, reflecting ongoing challenges. The stock shows a bearish technical trend with key support at $6. Recent Q2 2026 earnings beat expectations with EPS of $0.05 versus $0.02, but revenue declined year-over-year. Financials reveal negative net income margin of -9.98% and weak cash flow, with net cash outflow of $361.87 million in 2025. Analysts maintain a cautious stance amid soft demand in key markets.
The outlook remains challenging due to persistent revenue declines and profitability issues. Investment opportunities hinge on successful execution of turnaround strategies, but risks include intense competition and macroeconomic pressures. With a consensus price target of $5.96 below the current price, Wall Street sentiment is neutral to bearish, emphasizing the need for improved fundamentals to drive recovery.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
